总部在香港的加拿大公司开发出第一款AI设计的抗Covid药物,将在中国开始临床试验

metropolis

本站元老
注册
2010-12-10
消息
10,403
荣誉分数
2,190
声望点数
373

Canadian-founded company develops first AI-designed COVID-19 drug, starts clinical trials​


Tom Yun
Published Feb. 28, 2023 9:39 a.m. EST

For the first time ever, a drug for COVID-19 designed with artificial intelligence is headed to clinical trials.

Insilico Medicine, a Hong Kong-based AI pharmaceutical company, announced last Thursday its ISM3312 therapeutic would be starting clinical trials in China after its preclinical studies found that the drug "significantly reduces" viral load and inflammation in the lungs.

“Generative AI is transforming every area of human development,” Alex Zhavoronkov, Insilico's Canadian founder and CEO, said in a news release. “We’re extremely happy to announce that our second small molecule therapeutic generated using generative AI is now entering human clinical trials and there is a very clear timeline to demonstrate the discovery and development cycle.”

 
后退
顶部